The FDA granted approval to atezolizumab (Tecentriq), in combination with chemotherapy, for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). This is the second checkpoint immunotherapy approval for advanced SCLC.
Search for the latest news about atezolizumab